Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.43 |
| ▸ | SUV39H1 | O43463 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.43 |
| ▸ | RNF31 | Q96EP0 | 1/20 | 0.43 |
| ▸ | RBCK1 | Q9BYM8 | 1/20 | 0.43 |
| ▸ | SHARPIN | Q9H0F6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylgliotoxin SCHEMBL18652995 | 0.68 | EHMT2 (0.52) | EHMT2SUV39H1PKMFNTAFNTB | |
| Dimethylgliotoxin SCHEMBL13824181 | 0.68 | EHMT2 (0.52) | EHMT2SUV39H1PKMFNTAFNTB | |
| Bis(Dethio)Bis(Methylthio)Gliotoxin SCHEMBL18652994 | 0.68 | EHMT2 (0.52) | EHMT2SUV39H1PKMFNTAFNTB | |
| SCHEMBL29940479 | 0.66 | EHMT2 (0.40) | EHMT2SUV39H1PKMFNTAFNTB | |
| SCHEMBL13824179 | 0.61 | EHMT2 (0.53) | EHMT2SUV39H1PKMFNTAFNTB | |
| Gliotoxin SCHEMBL12018743 | 0.60 | EHMT2 (1.00) | EHMT2SUV39H1PKMFNTAFNTB | |
| SCHEMBL14021819 | 0.60 | EHMT2 (0.84) | EHMT2SUV39H1PKMFNTAFNTB | |
| Gliotoxin SCHEMBL12618354 | 0.60 | EHMT2 (1.00) | EHMT2SUV39H1PKMFNTAFNTB | |
| Gliotoxin SCHEMBL9667270 | 0.60 | EHMT2 (1.00) | EHMT2SUV39H1PKMFNTAFNTB | |
| Gliotoxin SCHEMBL13341245 | 0.60 | EHMT2 (1.00) | EHMT2SUV39H1PKMFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902202-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20090169504-A1 | Compounds and Pharmaceutical compositions for the treatment of Viral infections | IDENIX PHARMACEUTICALS, INC | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169504-A1 | Compounds and Pharmaceutical compositions for the treatment of Viral infections | HAVCR2, PYGL, GYS2 | EHMT2 4490/4885SUV39H1 3912/4885PKM 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.